ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2025
Genotyping R1336X and Eliminating the Pseudogene Amplification in Type 3 von Willebrand Disease Patients.
Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among inherited bleeding disorders, von Willebrand disease (VWD) is the most common disease worldwide. Type 3, the most severe form, is more prevalent in developing countries primarily due to consanguineous marriages. The enormous size of the von Willebrand factor gene, different kinds of mutations, and a partial unprocessed pseudogene make variation detection more difficult. To distinguish the VWF gene and the pseudogene sequence and prevent pseudogene amplification, it is necessary to utilize a suitable method. In this study, 42 unrelated VWD type 3 patients and 22 normal controls were included. Tetra-primer ARMS-PCR was applied for genotyping the single nucleotide variation, R1336X located on exon 28, which overlaps the pseudogene. The High percentage of heterozygotes (17% in VWD patients and 13% in controls) raised the suspicion of concomitant amplification of the VWF gene and it's pseudogene due to similarity in their primer-binding site sequence. To overcome this issue, we applied a two-step method using touch-down PCR followed by a tetra-primer ARMS-PCR. All cases with the heterozygous pattern on the first tetra-primer ARMS PCR were found to be normal homozygotes. In type 3 VWD patients genotyping is essential in decreasing the incidence of the disease, but the presence of a pseudogene with 97% homology makes it difficult. Applying appropriate methods that combine touch-down PCR and tetra-primer ARMS-PCR in terms of reliability, sensitivity, and accuracy can help to eliminate the pseudogene effect and diagnose more affected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.